Treatment of Experimental Choroidal Neovascularization via RUNX1 Inhibition
- 17 December 2020
- journal article
- research article
- Published by Elsevier in The American Journal of Pathology
- Vol. 191 (3) , 418-424
Abstract
No abstract availableKeywords
Funding Information
- E. Matilda Ziegler Foundation for the Blind
- National Institute of Neurological Disorders and Stroke
- Karl Kirchgessner Foundation
- Fundación Alfonso Martín Escudero
- National Eye Institute
- National Institute on Aging
This publication has 25 references indexed in Scilit:
- Immunology of age-related macular degenerationNature Reviews Immunology, 2013
- Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular DegenerationOphthalmology, 2012
- In Vivo Evaluation of Laser-Induced Choroidal Neovascularization Using Spectral-Domain Optical Coherence TomographyInvestigative Ophthalmology & Visual Science, 2011
- The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatmentEye, 2010
- An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillarisProceedings of the National Academy of Sciences, 2009
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- VEGF Expression and Receptor Activation in the Choroid during Development and in the AdultInvestigative Ophthalmology & Visual Science, 2006
- Quantitative enumeration of vascular smooth muscle cells and endothelial cells derived from bone marrow precursors in experimental choroidal neovascularizationExperimental Eye Research, 2005
- Polarized Vascular Endothelial Growth Factor Secretion by Human Retinal Pigment Epithelium and Localization of Vascular Endothelial Growth Factor Receptors on the Inner ChoriocapillarisThe American Journal of Pathology, 1999